JP4742030B2 - ポリマーが結合したグリコシル化ニューブラスチン - Google Patents

ポリマーが結合したグリコシル化ニューブラスチン Download PDF

Info

Publication number
JP4742030B2
JP4742030B2 JP2006510112A JP2006510112A JP4742030B2 JP 4742030 B2 JP4742030 B2 JP 4742030B2 JP 2006510112 A JP2006510112 A JP 2006510112A JP 2006510112 A JP2006510112 A JP 2006510112A JP 4742030 B2 JP4742030 B2 JP 4742030B2
Authority
JP
Japan
Prior art keywords
dimer
neublastin
cells
composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006510112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523709A5 (https=
JP2006523709A (ja
Inventor
ディナ ウェン−イー サ，
ブレーク アール． ペピンスキー，
アンソニー ロッソマンド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33310837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4742030(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2006523709A publication Critical patent/JP2006523709A/ja
Publication of JP2006523709A5 publication Critical patent/JP2006523709A5/ja
Application granted granted Critical
Publication of JP4742030B2 publication Critical patent/JP4742030B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006510112A 2003-04-18 2004-04-16 ポリマーが結合したグリコシル化ニューブラスチン Expired - Fee Related JP4742030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46389903P 2003-04-18 2003-04-18
US60/463,899 2003-04-18
PCT/US2004/011745 WO2004094592A2 (en) 2003-04-18 2004-04-16 Polymer-conjugated glycosylated neublastin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010271994A Division JP5415392B2 (ja) 2003-04-18 2010-12-06 ポリマーが結合したグリコシル化ニューブラスチン

Publications (3)

Publication Number Publication Date
JP2006523709A JP2006523709A (ja) 2006-10-19
JP2006523709A5 JP2006523709A5 (https=) 2007-05-17
JP4742030B2 true JP4742030B2 (ja) 2011-08-10

Family

ID=33310837

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006510112A Expired - Fee Related JP4742030B2 (ja) 2003-04-18 2004-04-16 ポリマーが結合したグリコシル化ニューブラスチン
JP2010271994A Expired - Fee Related JP5415392B2 (ja) 2003-04-18 2010-12-06 ポリマーが結合したグリコシル化ニューブラスチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010271994A Expired - Fee Related JP5415392B2 (ja) 2003-04-18 2010-12-06 ポリマーが結合したグリコシル化ニューブラスチン

Country Status (11)

Country Link
US (2) US8163875B2 (https=)
EP (3) EP2322205A1 (https=)
JP (2) JP4742030B2 (https=)
AT (1) ATE433759T1 (https=)
AU (1) AU2004233079B2 (https=)
CA (2) CA2864810A1 (https=)
DE (1) DE602004021648D1 (https=)
DK (1) DK1897552T3 (https=)
ES (2) ES2479942T3 (https=)
NZ (2) NZ543365A (https=)
WO (1) WO2004094592A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783310B2 (ja) 1993-01-28 1998-08-06 トヨタ車体株式会社 エンボス成形方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EA008743B1 (ru) * 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
WO2004094592A2 (en) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
EP2836518B1 (en) 2012-04-11 2019-01-02 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
HU187037B (en) 1983-04-19 1985-10-28 Tibor Sinko Rope-stretching device
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US5939524A (en) 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6063757A (en) 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
DE69636739T2 (de) 1995-12-21 2007-10-18 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US5754524A (en) 1996-08-30 1998-05-19 Wark; Barry J. Computerized method and system for analysis of an electrophoresis gel test
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
GB9718908D0 (en) * 1997-09-05 1997-11-12 Rowett Research Services Limit Proteins
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
HK1045528B (zh) 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
EP1115866A1 (en) 1998-09-22 2001-07-18 University of Maryland at Baltimore Cystine knot growth factor mutants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
MXPA01010692A (es) 1999-04-22 2004-09-06 Univ Zuerich Matrices de proteina modificadas para ingenieria de tejidos o liberacion controlada.
PT1223966E (pt) 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
CA2327208A1 (en) 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
NZ526610A (en) * 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the GDNF ligand family
DK1355936T3 (da) 2001-02-01 2007-10-29 Biogen Idec Inc Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) * 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
US20040077543A1 (en) 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
EP1389121B1 (en) 2001-04-24 2012-02-22 Purdue Research Foundation Method and compositions for treating mammalian nerve tissue injuries
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US7129085B2 (en) 2001-10-11 2006-10-31 Bristol-Myers Squibb Company Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
JP4310608B2 (ja) 2002-04-25 2009-08-12 東洋紡績株式会社 Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法
WO2004094592A2 (en) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
WO2005072764A2 (en) 2004-01-16 2005-08-11 Novocell, Inc. Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
EP1784486B1 (en) 2004-06-23 2011-10-05 TissueGene, Inc. Nerve regeneration
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
CA2577690C (en) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
DK1786454T3 (da) 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
US20080260702A1 (en) 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783310B2 (ja) 1993-01-28 1998-08-06 トヨタ車体株式会社 エンボス成形方法

Also Published As

Publication number Publication date
NZ574121A (en) 2011-06-30
US20120316109A1 (en) 2012-12-13
WO2004094592A2 (en) 2004-11-04
EP2322205A1 (en) 2011-05-18
CA2864810A1 (en) 2004-11-04
EP1618179A4 (en) 2008-03-05
US8163875B2 (en) 2012-04-24
JP2011084567A (ja) 2011-04-28
EP1618179B1 (en) 2014-05-07
JP5415392B2 (ja) 2014-02-12
WO2004094592A3 (en) 2006-04-27
AU2004233079A1 (en) 2004-11-04
US8642732B2 (en) 2014-02-04
ES2328640T3 (es) 2009-11-16
CA2522364A1 (en) 2004-11-04
EP1897552B1 (en) 2009-06-17
DE602004021648D1 (de) 2009-07-30
US20070238650A1 (en) 2007-10-11
JP2006523709A (ja) 2006-10-19
DK1897552T3 (da) 2009-10-05
EP1897552A1 (en) 2008-03-12
ES2479942T3 (es) 2014-07-25
NZ543365A (en) 2009-02-28
EP1618179A2 (en) 2006-01-25
CA2522364C (en) 2014-12-09
ATE433759T1 (de) 2009-07-15
AU2004233079B2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
JP5415392B2 (ja) ポリマーが結合したグリコシル化ニューブラスチン
US20110251267A1 (en) Methods of using polynucleotides encoding truncated glial cell line-derived neurotrophic factor
JP2012167119A (ja) ニューロパシーの疼痛を処置するためのニューブラスチンポリペプチドの使用
KR100915278B1 (ko) 인슐린-유사 성장 인자-1(ｉｇｆ-1) 및 폴리(에틸렌글라이콜)의 접합체
JPH11505548A (ja) グリア細胞系由来神経栄養因子（ｇｄｎｆ）蛋白産物を用いたハンチントン病の治療方法
ME00277B (me) Polimerni konjugati mutiranog neublastina
KR101215697B1 (ko) 뉴블라스틴 변형체
US20040077543A1 (en) Treatment using neublastin polypeptides
Debeljak et al. Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives
HK1155941A (en) Polymer-conjugated glycosylated neublastin
HK1113741B (en) Polymer-conjugated glycosylated neublastin
HK1113741A1 (en) Polymer-conjugated glycosylated neublastin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110426

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110509

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140513

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees